var data={"title":"Lidocaine (topical): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lidocaine (topical): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389804?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lidocaine-topical-drug-information\" class=\"drug drug_general\">see &quot;Lidocaine (topical): Drug information&quot;</a> and <a href=\"topic.htm?path=lidocaine-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lidocaine (topical): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26714119\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening and fatal events in infants and young children:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of lidocaine 2% viscous solution when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, lidocaine 2% viscous solution should generally not be used. For other conditions, the use of the product in patients less than 3 years should be limited to those situations where safer alternatives are not available or have been tried but failed. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">To decrease the risk of serious adverse events with use of lidocaine 2% viscous solution, instruct caregivers to strictly adhere to the prescribed dose and frequency of administration and store the prescription bottle safely out of reach of children.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768584\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alocane Emergency Burn Max Str [OTC];</li>\n      <li>Anastia;</li>\n      <li>AneCream [OTC];</li>\n      <li>AneCream5 [OTC];</li>\n      <li>Astero;</li>\n      <li>CidalEaze [DSC];</li>\n      <li>Eha;</li>\n      <li>EnovaRX-Lidocaine HCl;</li>\n      <li>Glydo;</li>\n      <li>LC-4 Lidocaine [OTC];</li>\n      <li>LC-5 Lidocaine [OTC];</li>\n      <li>LDO Plus;</li>\n      <li>Lido-K;</li>\n      <li>Lidocaine PAK;</li>\n      <li>Lidocin [DSC];</li>\n      <li>Lidoderm;</li>\n      <li>Lidopac;</li>\n      <li>Lidopin;</li>\n      <li>LidoRx;</li>\n      <li>Lidotral;</li>\n      <li>Lidotrans 5 Pak;</li>\n      <li>Lidotrex;</li>\n      <li>Lidovex;</li>\n      <li>Lidovin;</li>\n      <li>Lidozol;</li>\n      <li>Lidtopic Max;</li>\n      <li>LMX 4 Plus [OTC];</li>\n      <li>LMX 4 [OTC];</li>\n      <li>LMX 5 [OTC];</li>\n      <li>LTA 360 Kit [DSC];</li>\n      <li>Numbonex;</li>\n      <li>Predator [OTC];</li>\n      <li>Premium Lidocaine;</li>\n      <li>Prozena [DSC];</li>\n      <li>Prozena [OTC] [DSC];</li>\n      <li>RectaSmoothe [OTC];</li>\n      <li>RectiCare [OTC];</li>\n      <li>Topicaine 5 [OTC];</li>\n      <li>Topicaine [OTC] [DSC];</li>\n      <li>Tranzarel;</li>\n      <li>Venipuncture Px1 Phlebotomy;</li>\n      <li>Xolido XP [OTC];</li>\n      <li>Xolido [OTC];</li>\n      <li>Xryliderm;</li>\n      <li>Xylocaine;</li>\n      <li>Zeyocaine;</li>\n      <li>Zingo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768585\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Betacaine;</li>\n      <li>Lidodan;</li>\n      <li>Lidoderm;</li>\n      <li>Maxilene;</li>\n      <li>Xylocaine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529567\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Local Anesthetic, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Local Anesthetic, Transdermal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675240\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Smaller areas of treatment are recommended in younger or smaller patients (&lt;12 months or &lt;10 kg) or those with impaired elimination (Fein 2012); use lowest effective dose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Circumcision; anesthetic:</b> Topical: Cream: LMX 4 (lidocaine 4%): Full-term neonates: Apply 2 <b>g</b> of cream to foreskin and penis; occlude with plastic wrap; leave on for 20 to 30 minutes minutes prior  to circumcision (AAP 2012; Lehr 2005) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529633\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lidocaine-topical-drug-information\" class=\"drug drug_general\">see &quot;Lidocaine (topical): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Smaller areas of treatment are recommended in younger or smaller patients (&lt;12 months or &lt;10 kg) or those with impaired elimination (Fein 2012); use lowest effective dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthetic:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lidovex (lidocaine 3.75%): Infants, Children, and Adolescents: Dose varies with age, weight, and physical condition; apply a thin film to affected area 2 to 3 times daily as needed; maximum dose: 4.5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">LMX 4 (lidocaine 4%, liposomal): Children &gt; 2 years and Adolescents: Dose varies with age and weight; apply a thin film to affected area 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel, ointment: Children &ge;2 years and Adolescents: Dose varies with age and weight; apply to affected area up to 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg; not to exceed 300 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Jelly: Children and Adolescents: Dose varies with age and weight; maximum dose: 4.5 mg/kg not to exceed 600 mg in a 12-hour period </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Minor dermal procedures [eg,  peripheral IV cannulation, venipuncture, lumbar puncture, abscess drainage, joint aspiration]; anesthetic:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intradermal injection: Zingo: Venipuncture or peripheral IV catheter insertion: Children &ge;3 years and Adolescents:  Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, administer 1 to 3 minutes prior to the IV needle insertion; perform procedure within 10 minutes of application </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical: Cream LMX 4 (lidocaine 4%): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;4 years: 1 <b>g</b> applied to site 30 minutes prior to procedure; (Fein, 2012; Taddio, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;4 years and Adolescents &le;17 years: 1 to 2.5 <b>g</b> applied to site 30 minutes prior to procedure (Eichenfield 2002; Fein 2012; Koh 2004; Luhman 2004; Taddio 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For peripheral IV cannulation, some have recommended application to 6.25 cm<sup>2</sup> of skin (Sobanko 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Oral inflammation or irritation:</b> Topical: <b>Note:</b> Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported; AAP, AAPD, and ISMP strongly discourage use (AAP 2011; AAPD 2012; ISMP 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral solution (2% viscous): Dose should be adjusted according to patient&rsquo;s age, weight, and physical condition:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;3 years: 25 mg/dose (1.25 mL) applied to area with a cotton-tipped applicator no more frequently than every 3 hours; maximum: 4 doses per 12-hour period; should not be swallowed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;3 years and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum single dose: 300 mg; swished in the mouth and spit out no more frequently than every 3 hours; maximum: 4 doses per 12-hour period</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical solution (4%): <b>Note:</b> For use on mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract; use lowest effective dose. Children and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum single dose: 300 mg; applied with cotton applicator, cotton pack, or via spray; should not be swallowed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rectal pain, itching:</b> Topical: Cream: LMX 5 (lidocaine 5%): Children &ge;12 years and Adolescents: Apply to affected area up to 6 times daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin irritation:</b> Topical: Cream: LMX 4 (lidocaine 4%): Children &ge;2 years and Adolescents: Apply up to 3 to 4 times daily to intact skin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Anesthetic, topical:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LidaMantle, Lidovex: Skin irritation: Apply a thin film to affected area 2 to 3 times daily as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LMX 4: Skin irritation: Apply up to 3 to 4 times daily to intact skin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LMX 5: Relief of anorectal pain and itching: Apply to affected area up to 6 times/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel, ointment: Apply to affected area &le;4 times/day as needed (maximum dose: 4.5 mg/kg, not to exceed 300 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intradermal injection: Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, 1 to 3 minutes prior to needle insertion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Jelly: Maximum dose: 30 mL (600 mg) in any 12-hour period:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anesthesia of male urethra: 5 to 30 mL (100 to 600 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anesthesia of female urethra: 3 to 5 mL (60 to 100 mg)  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral topical solution (2% viscous):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anesthesia of the mouth: 15 mL swished in the mouth and spit out no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg/dose]; 8 doses per 24-hour period)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anesthesia of the pharynx: 15 mL gargled no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg/dose]; 8 doses per 24-hour period); may be swallowed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical patch: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lidoderm: Postherpetic neuralgia: Apply patch to most painful area. Up to 3 patches may be applied in a single application. Patch(es) may remain in place for up to 12 hours in any 24-hour period.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LidoPatch: Pain (localized): Apply patch to painful area. Patch may remain in place for up to 12 hours in any 24-hour period. No more than 1 patch should be used in a 24-hour period.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical solution (4%): <b>Note:</b> For use in mucous membranes of oral and nasal cavities and proximal GI tract; use lowest effective dose. Apply 1 to 5 mL (40 to 200 mg) to affected area (maximum dose: 4.5 mg/kg, not to exceed 300 mg/dose) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768875\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AneCream: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AneCream5: 5% (15 g, 30 g [DSC]) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LC-4 Lidocaine: 4% (45 g) [contains cetyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LC-5 Lidocaine: 5% (45 g) [contains cetyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidotral: 3.88% (85 g) [contains cetearyl alcohol, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidovex: 3.75% (60 g) [contains cetyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidovin: 3.95% (60 g) [contains peg-40 castor oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidozol: 3.75% (60 g) [contains peg-40 castor oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LMX 4: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LMX 5: 5% (15 g, 30 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RectaSmoothe: 5% (30 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RectiCare: 5% (15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3.88% (85 g); 4% (5 g, 15 g, 30 g, 120 g); 5% (15 g, 30 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CidalEaze: 3% (453.6 g [DSC]) [contains aluminum sulfate, calcium acetate, cetyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EnovaRX-Lidocaine HCl: 5% (60 g, 120 g) [contains cetyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EnovaRX-Lidocaine HCl: 10% (60 g, 120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidopin: 3% (28 g, 85 g); 3.25% (28 g, 85 g) [contains cetyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidtopic Max: 10% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Predator: 4% (63 g) [contains propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xolido: 2% (118 mL) [contains methylisothiazolinone]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xolido XP: 4% (118 mL) [contains methylisothiazolinone]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3% (28.3 g, 28.35 g, 85 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topicaine: 4% (10 g [DSC], 30 g [DSC], 113 g [DSC]) [contains benzyl alcohol, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topicaine 5: 5% (10 g, 30 g, 113 g) [contains benzyl alcohol, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alocane Emergency Burn Max Str: 4% (75 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Astero: 4% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LDO Plus: 4% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidocin: 3% (30 g [DSC], 120 g [DSC], 240 g [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LidoRx: 3% (10 mL, 30 mL, 90 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidotrex: 2% (28.33 g) [contains trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tranzarel: 4% (120 mL) [contains disodium edta, menthol, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (5 mL, 20 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glydo: 2% (6 mL, 11 mL) [pvc free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (5 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Jet-injector, Intradermal, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zingo: 0.5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AneCream: 4% [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidopac: 5% [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidotrans 5 Pak: 5% [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LMX 4 Plus: 4% [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xryliderm: 5% [contains edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zeyocaine: 5%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Venipuncture Px1 Phlebotomy: 2% [latex free; contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anastia: 2.75% (15 g) [contains cetyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eha: 4% (88 mL) [contains methylisothiazolinone]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lido-K: 3% (177 mL) [contains cetyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Numbonex: 2.75% (30 g) [contains cetyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3% (118 mL, 177 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidocaine PAK: 5% (30 g) [contains polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premium Lidocaine: 5% (50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (30 g, 35.44 g, 50 g, 150 g [DSC], 250 g [DSC], 2500 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidoderm: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prozena: 4% (5 ea [DSC], 15 ea [DSC], 30 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (1 ea, 15 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xylocaine: 4% (50 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Mouth/Throat, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (15 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Mouth/Throat, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LTA 360 Kit: 4% (4 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4% (4 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768595\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23884417\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=lidocaine-topical-drug-information\" class=\"drug drug_general\">see &quot;Lidocaine (topical): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">EnovaRX-Lidocaine, and Lidtopic Max creams are compounded from kits. Refer to manufacturer&rsquo;s package insert for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51192551\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">ZTlido (lidocaine 1.8% topical system): FDA approved March 2018; availability anticipated in 2018. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529684\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream: Apply to affected area; occlusive dressing may be applied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LMX-4: Minor dermal procedure (peripheral IV cannulation, venipuncture):  Infants and Children: Apply to skin at least 30 minutes before procedure; in most trials, occlusion of the application site was used (Koh 2004; Luhman 2004; Taddio 2004) while another trial showed that occlusion was not required (Eichenfiled 2002); however, occlusion of the site may be helpful in active infants and children to hold cream in place </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel (Topicaine): Apply a moderately thick layer to affected area (~<sup>1</sup>/<sub>8</sub>&quot; thick). Allow time for numbness to develop (~20 to 60 minutes after application). When used prior to laser surgery, avoid mucous membranes; remove prior to laser treatment.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intradermal injection: Refer to manufacturer&rsquo;s labeling for administration technique. Apply intradermal lidocaine 1 to 3 minutes prior to needle insertion; perform procedure within 10 minutes following application. Application of <b>one</b> additional intradermal lidocaine at a new location is acceptable after a failed attempt at peripheral IV cannulation; multiple administrations of intradermal lidocaine at the same location are not recommended. Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier. When removing the device from the pouch, be careful not to touch the purple outlet (open end) to avoid contamination; do not use if the device has been dropped or the pouch is damaged or torn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution (2% viscous): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mouth irritation or inflammation: Have patient swish medication around mouth and then spit it out. In children &lt;3 years, apply small amount to affected area with cotton-tipped applicator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pharyngeal anesthesia: Adults: Patient should gargle and may swallow medication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Topical patch: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">  Lidoderm: Apply to intact skin to cover most painful area immediately after removal from protective envelope. May be cut (with scissors, prior to removal of release liner) to appropriate size. Clothing may be worn over application area. After removal from skin, fold used patches so the adhesive side sticks to itself; avoid contact with eyes. Remove immediately if burning sensation occurs. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). Dispose of patch properly and keep out of reach of children. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LidoPatch: Remove protective film and apply to painful area. Avoid contact with eyes or mucous membranes. Do not apply to open wounds or sensitive skin and do not bandage tightly. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12705682\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">All formulations: Store at room temperature; see product-specific labeling for any additional storage requirements. Store and dispose of products out of the reach of children and pets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529604\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">In general, local anesthetic for oral mucous membrane; laser/cosmetic surgeries; minor burns, cuts, and abrasions of the skin; specific uses will vary based on product formulation (FDA approved in adults; refer to product specific information regarding FDA approval in pediatric patients) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Product-specific indications: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream: Temporary relief of pain and itching due to minor cuts, scrapes, burns, sunburn, minor skin irritations, and insect bites (OTC use: Lidovex 3.75%: FDA approved in pediatric patients [age not specified] and adults; LMX 4: FDA approved in ages &ge;2 years and adults); liposomal cream (LMX 4) has also been used as topical anesthetic for minor dermal procedures (eg, venipuncture, peripheral IV cannulation) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intradermal injection (Zingo): Topical local analgesia prior to peripheral intravenous (IV) cannulation (FDA approved in ages 3 through 18 years) and topical local analgesia prior to venipuncture (FDA approved in ages &ge;3 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical patch (Lidoderm): Relief of allodynia (painful hypersensitivity) and  postherpetic neuralgia (FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal (LMX 5): Temporary relief of pain and itching due to anorectal disorders (FDA approved in ages &ge;12 years and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution (2% viscous): Topical anesthesia of irritated oral mucous membranes and pharyngeal tissue (FDA approved in infants, children, and adults); <b>Note:</b> Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported (AAP, 2011; AAPD, 2012; ISMP, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical solution (4%): Topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract (FDA approved in children [age not specified] and adults); <b>Note:</b> Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported (AAP, 2011; AAPD, 2012; ISMP, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768638\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Adverse effects vary with formulation and extent of systemic absorption; children may be at increased risk. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Bradycardia, edema (intradermal powder)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Apprehension, confusion, dizziness, drowsiness, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: dermatitis, erythema (intradermal powder), exacerbation of pain (topical patch), petechia (intradermal powder), pruritus (intradermal powder), skin depigmentation (topical patch), skin edema (topical patch), skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea (intradermal powder), vomiting (intradermal powder)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic and oncologic: Bruise (topical patch), methemoglobinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Local irritation (topical patch) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768633\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; traumatized mucosa, bacterial infection at the site of application (lotion and Lidovex only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768634\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Familial malignant hyperthermia: Many drugs used during the conduct of anesthesia may trigger familial malignant hyperthermia; not known whether amide-type local anesthetics trigger this reaction. However, standard protocol for management should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation. If familial malignant hyperthermia is confirmed, discontinue triggering agent and initiate appropriate therapy (eg, oxygen, dantrolene) and other supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Use with caution in patients with known drug sensitivities. Allergic reactions (cutaneous lesions, urticaria, edema, or anaphylactoid reactions) may be a result of sensitivity to lidocaine (rare) or preservatives used in formulations. Patients allergic to para-aminobenzoic acid (PABA) derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Local effects: Irritation, sensitivity and/or infection may occur at the site of application; discontinue use and institute appropriate therapy if local effects occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Systemic adverse effects: Potentially life-threatening side effects (eg, irregular heart beat, seizures, coma, respiratory depression, death) have occurred when used prior to cosmetic procedures. Excessive dosing for any indication (eg, application to large areas, use above recommended dose, application to denuded or inflamed skin, or wearing of device for longer than recommended), smaller patients, and/or impaired elimination may lead to increased absorption and systemic toxicity; patient should adhere strictly to recommended dosage and administration guidelines; serious adverse effects may require the use of supportive care and resuscitative equipment; lidocaine toxicity may occur at blood concentrations above 5 mcg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding tendencies/platelet disorders: Intradermal injection: Use with caution; may have a higher risk of superficial dermal bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with severe shock or heart block.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermal integrity reduced: Application to broken or inflamed skin may lead to increased systemic absorption; use caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Familial malignant hyperthermia: May potentially trigger malignant hyperthermia; follow standard protocol for identification and treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use caution in patients with severe hepatic disease due to diminished ability to metabolize systemically-absorbed lidocaine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pseudocholinesterase deficiency: Use with caution; these patients have a greater risk of developing toxic plasma concentrations of lidocaine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sepsis/severely traumatized mucosa: Use with extreme caution in the presence of sepsis and/or severely traumatized mucosa due to an increased risk of rapid systemic absorption at application site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intradermal injection: Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical cream, liquid, lotion, gel, and ointment: Do not leave on large body areas for &gt;2 hours. Not for ophthalmic use. Some products are not recommended for use on mucous membranes; consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical oral solution: When used in mouth or throat, topical anesthesia may impair swallowing and increase aspiration risk. Avoid food for &ge;60 minutes following oral or throat application. This is especially important in the pediatric population. Numbness may increase the danger of tongue/buccal biting trauma; ingesting food or chewing gum should be avoided while mouth or throat is anesthetized. Excessive doses or frequent application may result in high plasma levels and serious adverse effects; strictly adhere to dosing instructions. Use measuring devices to measure the correct volume, if applicable, to ensure accuracy of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical patch: Apply only on intact skin. Do not use around or in the eyes. To avoid accidental ingestion by children, store and dispose of products out of the reach of children. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution; acutely ill patients should be given reduced doses commensurate with their age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly and debilitated patients: Use with caution; elderly and debilitated patients should be given reduced doses commensurate with their age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Oral topical solution/viscous: <b>[US Boxed Warning]: Life-threatening and fatal events in infants and young children:</b> Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients &lt;3 years have been reported with use of lidocaine 2% viscous solution when it was not administered in strict adherence to the dosing and administration recommendations. Lidocaine 2% viscous solution should generally not be used for teething pain. For other conditions, the use of lidocaine 2% viscous solution in patients &lt;3 years should be limited to those situations where safer alternatives are not available or have been tried but failed. To decrease the risk of serious adverse events, instruct caregivers to strictly adhere to the prescribed dose and frequency of administration, and store the prescription bottle safely out of reach of children. Multiple cases of seizures (including fatalities) have occurred in pediatric patients using viscous lidocaine for oral discomfort, including use for teething pain and stomatitis (Curtis 2009; Giard 1983; Gonzalez del Ray 1994; Hess 1988; Mofenson 1983; Puczynski 1985; Rothstein 1982; Smith 1992). The FDA recommends against using topical OTC medications for teething pain as some products may cause harm. The American Academy of Pediatrics (AAP) recommends managing teething pain with a chilled (not frozen) teething ring or gently rubbing/massaging with the caregiver's finger. Use of topical anesthetics for teething is discouraged by the AAP, the American Academy of Pediatric Dentistry, and the ISMP (AAP 2012; AAPD 2012; ISMP 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use with caution; children should be given reduced doses commensurate with their age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heart beats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to cover the skin following application. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022202\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In infants and children, seizures (some fatal) have been reported following topical lidocaine ingestion at serum concentrations within the therapeutic range of 1 to 5 mcg/mL (Curtis 2009); others have reported toxic effects with excessive doses or frequent application of topical oral lidocaine solution that resulted in high plasma concentrations. Multiple cases of seizures, including fatalities, have occurred in pediatric patients using viscous lidocaine for oral discomfort (eg, teething pain, herpetic gingivostomatitis) (Curtis 2009; Giard 1983; Gonzalez del Rey 1994; Hess 1988; Mofenson 1983; Puczynski 1985; Rothstein 1982; Smith 1992). Lidocaine oral solution is not approved for treatment of teething pain or discomfort; off-label use is strongly discouraged and should be avoided. When used for oral irritation, the solution should not be swallowed, but should be applied topically with a cotton swab to individual lesions or the excess should be expectorated (swish and spit). Toxicology data suggests that in infants and children&lt;6 years, ingestion of as little as 5 mL of lidocaine may result in serious toxicity and emergency care should be sought (Curtis 2009). Additionally, the FDA recommends against using topical OTC medications for teething pain as some products may cause harm; the use of OTC topical anesthetics (eg, benzocaine) for teething pain is also discouraged by AAP, and The American Academy of Pediatric Dentistry (AAP 2011; AAPD 2012). The AAP recommends managing teething pain with a chilled (not frozen) teething ring or gently rubbing/massaging with the caregiver's finger.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Topical patches (both used and unused) may cause toxicities in children; used patches still contain large amounts of lidocaine; store and dispose patches out of the reach of children; efficacy of patches in pediatric patients has not been evaluated due to safety concerns.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768676\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768677\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16015&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768628\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768629\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies using the systemic injection. Lidocaine and its metabolites cross the placenta and can be detected in the fetal circulation following injection (Cavalli 2004; Mitani 1987). The amount of lidocaine absorbed topically (and therefore available systemically to potentially reach the fetus) varies by dose administered, duration of exposure, and site of application. Cumulative exposure from all routes of administration should be considered. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768728\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14294120\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Intradermal injection: 1 to 3 minutes; Topical: 3 to 5 minutes; Transdermal: ~4 hours (Davies 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Intradermal injection: 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Transdermal (5%): 3% &plusmn; 2%  (following application of 3 patches), extent and rate variable; dependent upon concentration, dose, application site, and duration of exposure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 60% to 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP1A2 (major) and CYP3A4 (minor); active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: IV: 1.5 to 2 hours; prolonged 2-fold or more in hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Transdermal (5%): 11 hours (following application of 3 patches)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;10% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8768877\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (AneCream External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (15 g): $19.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (AneCream5 External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (15 g): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidocaine (Anorectal) External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (30 g): $16.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (15 g): $19.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidocaine HCl External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3% (85 g): $122.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.88% (85 g): $490.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidotral External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.88% (85 g): $1,498.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidtopic Max External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (30 mL): $182.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (LMX 4 External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (5 g): $8.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (LMX 5 External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (15 g): $33.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (RectaSmoothe External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (30 g): $19.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (RectiCare External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (15 g): $15.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Alocane Emergency Burn Max Str External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (75 mL): $6.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Astero External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (30 mL): $313.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Glydo External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (6 mL): $7.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (LDO Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (30 mL): $398.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Lidocaine HCl External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (5 mL): $7.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Lidotrex External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (28.33 g): $1,859.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Topicaine 5 External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (30 g): $19.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Tranzarel External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (120 mL): $708.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Jet-injector</b> (Zingo Intradermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $148.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (AneCream External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (1): $33.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lidocaine-Transparent Dressing External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (1): $30.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lidotrans 5 Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1): $1,620.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LMX 4 Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (1): $48.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Venipuncture Px1 Phlebotomy External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (1): $981.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Xryliderm External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1): $4,970.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Zeyocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (Oint) (1): $1,888.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Lidocaine HCl External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3% (177 mL): $69.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Lidocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (35.44 g): $301.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Lidocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (30): $308.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Lidoderm External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1): $18.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lidocaine HCl External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (50 mL): $48.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lidocaine HCl Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (4 mL): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Xylocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (50 mL): $21.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390233\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Betacaine (IL);</li>\n      <li>Chalocaine Jelly (TH);</li>\n      <li>Dermomax (BR);</li>\n      <li>Dimecaina (CL);</li>\n      <li>Dynexan (CH, FR);</li>\n      <li>Esracain Jelly (IL);</li>\n      <li>Gesicain Jelly (IN);</li>\n      <li>Gesicain Ointment (IN);</li>\n      <li>Gesicain Viscous (IN);</li>\n      <li>Happycain (KR);</li>\n      <li>Kenergon (CH);</li>\n      <li>Lambdalina (ES);</li>\n      <li>Lecasin (KR);</li>\n      <li>Leostesin Jelly (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Leostesin Ointment (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Lidocain Gel (FI);</li>\n      <li>Lidocain Spray (BG);</li>\n      <li>Lidoderm (GR);</li>\n      <li>Lidopain (BD);</li>\n      <li>Lidotop Cataplasma (KR);</li>\n      <li>Lignocaine Gel (AU);</li>\n      <li>Lignopad (HK, MY);</li>\n      <li>Peterkaien (ZA);</li>\n      <li>Pisacaina (EC);</li>\n      <li>Power Gel (KR);</li>\n      <li>Prolong 1000 (CL, PE);</li>\n      <li>Rialocaine (QA);</li>\n      <li>Rocky Gel (KR);</li>\n      <li>Roxicaina (CO);</li>\n      <li>Solarcaine (HK);</li>\n      <li>Stud 100 (AU, IL, MT);</li>\n      <li>Versatis (BE, CL, CO, CR, DO, EC, EE, ES, GT, HN, HR, HU, LT, LU, LV, MT, NI, PA, PE, RO, RU, SE, SK, SV, UA);</li>\n      <li>Versatis Plaster (GB, IE);</li>\n      <li>Xilonest (PE);</li>\n      <li>Xilotane Oral (PT);</li>\n      <li>Xylocain (IS);</li>\n      <li>Xylocain Aerosol (DK, SE);</li>\n      <li>Xylocain Gel (AT, CH, DE, DK, FI, NO, SE);</li>\n      <li>Xylocain Liniment (DK);</li>\n      <li>Xylocain Ointment (AT, CH, DE, FI);</li>\n      <li>Xylocain Salve (DK);</li>\n      <li>Xylocain Spray (AT, CH, DE, NO);</li>\n      <li>Xylocain Viscous (AT, CH);</li>\n      <li>Xylocain Viskos (DE, SE);</li>\n      <li>Xylocain Visks (FI);</li>\n      <li>Xylocaina Ointment (IT);</li>\n      <li>Xylocaina Pomada (AR);</li>\n      <li>Xylocaina Spray (CO, IT);</li>\n      <li>Xylocaine (LK, SI);</li>\n      <li>Xylocaine Aerosol (AU, HK, NL);</li>\n      <li>Xylocaine Gel (AE, BE, BH, CY, EG, FR, GR, IE, IQ, IR, JO, KW, LB, LY, OM, PK, QA, SA, SY, YE);</li>\n      <li>Xylocaine Jalea (UY);</li>\n      <li>Xylocaine Jelly (BF, BJ, CI, ET, GH, GM, GN, HK, ID, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, NZ, PH, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, VN, ZM, ZW);</li>\n      <li>Xylocaine Ointment (AE, AU, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PH, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Xylocaine Pump Spray (AU, EE);</li>\n      <li>Xylocaine Spray (BE, BF, BJ, CI, ET, GB, GH, GM, GN, GR, HK, ID, IL, KE, KR, LI, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, PH, PL, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Xylocaine Topical Solution (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Xylocaine Viscosa (PY);</li>\n      <li>Xylocaine Viscous (GB, IE, IN, MY, TH);</li>\n      <li>Xylocaine Viscous Topical Solution (AU, GB);</li>\n      <li>Xylocaine Viscus (GR);</li>\n      <li>Xylocaine Viskeus Topical Solution (NL);</li>\n      <li>Xylone (BD);</li>\n      <li>Ziagel (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatric Dentistry. Guideline on infant oral health care. 2012. Available at http://www.aapd.org/media/Policies_Guidelines/G_infantOralHealthCare.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Oral Health Initiative. A pediatric guide to children&rsquo;s oral health. January, 2011. Available at http://www2.aap.org/commpeds/dochs/oralhealth/docs/OralHealthFCpagesF2_2_1.pdf </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Task Force on Circumcision. Male circumsion. <i>Pediatrics</i>. 2012;130:e756.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cavalli Rde C, Lanchote VL, Duarte G, et al, &quot;Pharmacokinetics and Transplacental Transfer of Lidocaine and its Metabolite For Perineal Analgesic Assistance to Pregnant Women,&quot; <i>Eur J Clin Pharmacol</i>, 2004, 60(8):569-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15365654/pubmed\" target=\"_blank\" id=\"15365654\">15365654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curtis LA, Dolan TS, Seibert HE. Are one or two dangerous? Lidocaine and topical anesthetic exposures in children. <i>J Emerg Med</i>. 2009;37(1):32-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/18280086/pubmed\" target=\"_blank\" id=\"18280086\">18280086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies PS and Galer BS, &quot;Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia,&quot; <i>Drugs</i>, 2004, 64(9):937-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15101784/pubmed\" target=\"_blank\" id=\"15101784\">15101784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dryden RM, Lo MW. Breast milk lidocaine levels in tumescent liposuction. <i>Plast Reconstr Surg</i>. 2000;105(6):2267-2268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/10839430/pubmed\" target=\"_blank\" id=\"10839430\">10839430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eichenfield LF, Funk A, Fallon-Friedlander S, Cunningham BB. A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. <i>Pediatrics</i>. 2002;109:1093-1099.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/12042548/pubmed\" target=\"_blank\" id=\"12042548\">12042548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fein JA, Zempsky WT, Cravero JP, Committee on Pediatric Emergency Medicine and Section on Anesthesiology and Pain Medicine. Relief of pain and anxiety in pediatric patients in emergency medical systems. <i>Pediatrics</i>. 2012;130:e1391-1405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/23109683/pubmed\" target=\"_blank\" id=\"23109683\">23109683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giard MJ, Uden DL, Whitlock DJ, Watson DM. Seizures induced by oral viscous lidocaine. <i>Clin Pharm</i>. 1983;2(2):110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6883940/pubmed\" target=\"_blank\" id=\"6883940\">6883940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonzalez del Rey J, Wason S, Druckenbrod RW. Lidocaine overdose: another preventable case? <i>Pediatr Emerg Care</i>. 1994;10(6): 344-346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/7899121/pubmed\" target=\"_blank\" id=\"7899121\">7899121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giuliani M, Grossi GB, Pileri M, Lajolo C, Casparrini G. Could local anesthesia while breast-feeding be harmful to infants? <i>J Pediatr Gastroenterol Nutr</i>. 2001;32(2):142-144.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/11321382/pubmed\" target=\"_blank\" id=\"11321382\">11321382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hess GP, Walson PD. Seizures secondary to oral viscous lidocaine. <i>Ann Emerg Med</i>. 1988;17(7):725-727.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3382075/pubmed\" target=\"_blank\" id=\"3382075\">3382075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP). Topical anesthetics for teething infants. ISMP Medication Safety Alert. January 14, 2014. Available at http://www.ismp.org/newsletters/acutecare/issues/20140116.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koh JL, Harrison D, Myers R, Dembinski R, Turner H, McGraw T. A randomized, double-blind comparison study of EMAL and ELA-Max for topical anesthesia in children undergoing intravenous insertion. <i>Paediatr Anesth</i>. 2004;14(12):977-982.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15601345/pubmed\" target=\"_blank\" id=\"15601345\">15601345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lebedevs TH, Wojnar-Horton RE, Yapp P, et al, &quot;Excretion of Lignocaine and its Metabolite Monoethylglycinexylidide in Breast Milk Following its Use in a Dental Procedure. A Case Report,&quot; <i>J Clin Periodontol</i>, 1993, 20(8):606-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/8408724/pubmed\" target=\"_blank\" id=\"8408724\">8408724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehr VT, Cepeda E, Frattarelli DA, et al, &quot;Lidocaine 4% Cream Compared With Lidocaine 2.5% and Prilocaine 2.5% or Dorsal Penile Block for Circumcision,&quot; <i>Am J Perinatol</i>, 2005, 22(5):231-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/16041631/pubmed\" target=\"_blank\" id=\"16041631\">16041631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lidoderm (lidocaine patch) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lidovex (lidocaine cream) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals, LLC; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LMX5 cream (lidocaine topical) [prescribing information. Ferndale, MI: Ferndale Laboratories, Inc; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luhmann J, Hurt S, Shootman M, Kennedy R. A comparison of buffered lidocaine versus ELA-Max before peripheral intravenous catheter insertions in children. <i>Pediatrics</i>. 2004;133:e217-220.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitani GM, Steinberg I, Lien EJ, et al, &quot;The Pharmacokinetics of Antiarrhythmic Agents in Pregnancy and Lactation,&quot; <i>Clin Pharmacokinet</i>, 1987, 12(4):253-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3297463/pubmed\" target=\"_blank\" id=\"3297463\">3297463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mofenson HC, Caraccio TR, Miller H, Greensher J. Lidocaine toxicity from topical mucosal application. With a review of the clinical pharmacology of lidocaine. <i>Clin Pediatr (Phila)</i>, 1983;22(3):190-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6825363/pubmed\" target=\"_blank\" id=\"6825363\">6825363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega D, Viviand X, Lorec AM, et al, &quot;Excretion of Lidocaine and Bupivacaine in Breast Milk Following Epidural Anesthesia for Cesarean Delivery,&quot; <i>Acta Anaesthesiol Scand</i>, 1999, 43(4):394-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/10225071/pubmed\" target=\"_blank\" id=\"10225071\">10225071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Puczynski MS, Ow EP, Rust C. Cardiopulmonary arrest due to misuse of viscous lidocaine. <i>Arch Otolaryngol</i>. 1985;111(11):768-769.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/4051869/pubmed\" target=\"_blank\" id=\"4051869\">4051869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rothstein P, Dornbusch J, Shaywitz BA. Prolonged seizures associated with the use of viscous lidocaine. <i>J Pediatr</i>. 101(3):461-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/7108671/pubmed\" target=\"_blank\" id=\"7108671\">7108671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sakai RI, Lattin JE. Lidocaine ingestion. <i>Am J Dis Child</i>. 1980;1344(3):323.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/7361745/pubmed\" target=\"_blank\" id=\"7361745\">7361745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith M, Wolfram W, Rose R. Toxicity-seizures in an infant caused by (or related to) oral viscous lidocaine use. <i>J Emerg Med</i>. 1992;10(5):587-590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/1401862/pubmed\" target=\"_blank\" id=\"1401862\">1401862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sobanko JF, Miller CJ, Alster TS. Topical anesthetics for dermatologic procedures: a review.<i> Dermatol Surg</i>. 2012;38(5):709-721.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/22243434 /pubmed\" target=\"_blank\" id=\"22243434 \">22243434 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taddio A, Soin HK, Schuh S, Koren G, Scolnik D. Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial. <i>CMAJ</i>. 2005;172(13):1691-1695.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15967972/pubmed\" target=\"_blank\" id=\"15967972\">15967972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xylocaine 2% jelly (lidocaine hydrochloride) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC; June 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeisler JA, Gaarder TD, De Mesquita SA. Lidocaine excretion in breast milk. <i>Drug Intell Clin Pharm</i>. 1986;20(9):691-693.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3757781/pubmed\" target=\"_blank\" id=\"3757781\">3757781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zingo (lidocaine) [prescribing information]. Mundelein, IL: Medline Industries, Inc; November 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16015 Version 258.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26714119\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8768584\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8768585\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10529567\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675240\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10529633\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8768875\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8768595\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23884417\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51192551\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10529684\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F12705682\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10529604\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8768638\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8768633\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8768634\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022202\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8768676\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8768677\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8768628\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8768629\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8768728\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F14294120\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8768877\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390233\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16015|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lidocaine-topical-drug-information\" class=\"drug drug_general\">Lidocaine (topical): Drug information</a></li><li><a href=\"topic.htm?path=lidocaine-topical-patient-drug-information\" class=\"drug drug_patient\">Lidocaine (topical): Patient drug information \t</a></li></ul></div></div>","javascript":null}